Literature DB >> 25312673

Live attenuated and inactivated viral vaccine formulation and nasal delivery: potential and challenges.

José L Tlaxca1, Scott Ellis2, Richard L Remmele3.   

Abstract

Vaccines are cost-effective for the prevention of infectious diseases and have significantly reduced mortality and morbidity. Novel approaches are needed to develop safe and effective vaccines against disease. Major challenges in vaccine development include stability in a suitable dosage form and effective modes of delivery. Many live attenuated vaccines are capable of eliciting both humoral and cell mediated immune responses if physicochemically stable in an appropriate delivery vehicle. Knowing primary stresses that impart instability provides a general rationale for formulation development and mode of delivery. Since most pathogens enter the body through the mucosal route, live-attenuated vaccines have the advantage of mimicking natural immunization via non-invasive delivery. This presentation will examine aspects of formulation design, types of robust dosage forms to consider, effective routes of delivery (invasive and noninvasive), and distinctions between live attenuated or inactivated vaccines.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug delivery; Formulation; Killed-inactivated; Live-attenuated; Nasal; Stability; Vaccines

Mesh:

Substances:

Year:  2014        PMID: 25312673     DOI: 10.1016/j.addr.2014.10.002

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  16 in total

1.  Novel antigen delivery systems.

Authors:  Maria Trovato; Piergiuseppe De Berardinis
Journal:  World J Virol       Date:  2015-08-12

Review 2.  Intranasal immunization with dry powder vaccines.

Authors:  Tania F Bahamondez-Canas; Zhengrong Cui
Journal:  Eur J Pharm Biopharm       Date:  2017-11-06       Impact factor: 5.571

3.  A Measles Virus-Based Vaccine Candidate Mediates Protection against Zika Virus in an Allogeneic Mouse Pregnancy Model.

Authors:  Cindy Nürnberger; Bianca S Bodmer; Anna H Fiedler; Gülsah Gabriel; Michael D Mühlebach
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

4.  Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.

Authors:  Hui Wu; Yuanyuan Bao; Xiang Wang; Dongming Zhou; Wenzhe Wu
Journal:  Hum Vaccin Immunother       Date:  2017-01-27       Impact factor: 3.452

5.  Downregulating viral gene expression: codon usage bias manipulation for the generation of novel influenza A virus vaccines.

Authors:  Steven F Baker; Aitor Nogales; Luis Martínez-Sobrido
Journal:  Future Virol       Date:  2015-06       Impact factor: 1.831

Review 6.  Mucosal immunoglobulins of teleost fish: A decade of advances.

Authors:  Irene Salinas; Álvaro Fernández-Montero; Yang Ding; J Oriol Sunyer
Journal:  Dev Comp Immunol       Date:  2021-03-27       Impact factor: 3.605

Review 7.  Reverse Genetics Approaches for the Development of Influenza Vaccines.

Authors:  Aitor Nogales; Luis Martínez-Sobrido
Journal:  Int J Mol Sci       Date:  2016-12-22       Impact factor: 5.923

Review 8.  Diagnostic and Vaccination Approaches for Newcastle Disease Virus in Poultry: The Current and Emerging Perspectives.

Authors:  Muhammad Bashir Bello; Khatijah Yusoff; Aini Ideris; Mohd Hair-Bejo; Ben P H Peeters; Abdul Rahman Omar
Journal:  Biomed Res Int       Date:  2018-08-05       Impact factor: 3.411

Review 9.  Development of vaccines for SARS-CoV-2.

Authors:  Wern Hann Ng; Xiang Liu; Suresh Mahalingam
Journal:  F1000Res       Date:  2020-08-17

Review 10.  African swine fever: Etiology, epidemiological status in Korea, and perspective on control.

Authors:  Dongwan Yoo; Hyunil Kim; Joo Young Lee; Han Sang Yoo
Journal:  J Vet Sci       Date:  2020-03       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.